Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic mesenchymal stem cell transplantation for recent-onset type 1 diabetes
IRCT20210925052566N1Phase 2Completed
- Sponsor
- Endocrinology and Metabolism Research Institute
- Start
- May 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSCC_ASC and placenta-derived mesenchymal stem cells in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Endocrinology and Metabolism Research Institute. Primary endpoints: Daily insulin requirement, HbA1c and 3 more. Started May 2022; status: completed.
02
Drugs
CSCC_ASCplacenta-derived mesenchymal stem cells
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on IRCT20210925052566N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210925052566N1.